SCHEMBL27201290

SCHEMBL27201290

Nc1cc(N2CCCC(O)(c3ccccc3Br)C2)nc(N)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 8/20 0.39
HRH3 Q9Y5N1 1/20 0.39
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
MAPT P10636 1/20 0.33
GFER P55789 1/20 0.33
NUDT1 P36639 2/20 0.33
HTR3A P46098 1/20 0.32
EIF2AK4 Q9P2K8 1/20 0.32
NCF1 P14598 1/20 0.32
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30885210 1.00 HRH4 (0.39) HRH4HRH3USP2LMNATSHR
SCHEMBL30834210 0.86 HRH3 (0.43) HRH4HRH3USP2LMNATSHR
SCHEMBL27201588 0.86 HRH3 (0.43) HRH4HRH3USP2LMNATSHR
SCHEMBL30885257 0.84 HRH4 (0.39) HRH4HRH3USP2LMNATSHR
SCHEMBL27201284 0.84 HRH4 (0.39) HRH4HRH3USP2LMNATSHR
SCHEMBL30885262 0.83 HRH3 (0.42) HRH4HRH3USP2LMNATSHR
SCHEMBL27201354 0.83 HRH3 (0.42) HRH4HRH3USP2LMNATSHR
SCHEMBL27201292 0.79 HRH3 (0.44) HRH4HRH3USP2LMNATSHR
SCHEMBL30885299 0.79 HRH3 (0.44) HRH4HRH3USP2LMNATSHR
SCHEMBL5742403 0.76 HRH4 (0.44) HRH4HRH3USP2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US claimed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO claimed
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP HRH4 4074/4885HRH3 4300/4885USP2 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.